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1. Introduction 
Puberty represents a particular period of life characterized by hormonal changes and 
physical and psychological modifications leading children from childhood to adolescence. 
During this period, menarche represents the most important event in females. Age of 
menarche is different among populations and has been recognized as an useful marker of 
socio-economic status, as well as dietary and environmental patterns (Chumlea et al., 2003; 
Swenson & Havens, 1987; Thomas et al., 2001). Generally, the first menstrual cycle takes 
place between 12 and 13 years of age, with 98% of girls having menarche by 15 years of age 
(Diaz, 2006). The normal range for menstrual cycles is between 21 and 45 days, with flow 
length varying from 2 to 7 days (Flug et al., 1984; World Health Organization Task Force on 
Adolescent Reproductive Health, 1986). During the first 2 years after menarche, menses 
length is often abnormal due to immaturity of the hypothalamic-pituitary-ovarian axis 
(Diaz, 2006); however, cycles range can be regular also in the first gynecologic year (Flug et 
al., 1984; World Health Organization Task Force on Adolescent Reproductive Health, 1986). 
Amenorrhea is defined as the complete absence or anomalous cessation of menstrual cycles 
in females during reproductive years. Just in three situations amenorrhea is considered 
physiological: during pregnancy, lactation and menopause. In all other situations, 
amenorrhea can be due to many pathological conditions and merits a careful assessment. 
Amenorrhea is classified as primary and secondary according to its occurrence before or 
after menarche, respectively (The Practice Committee of American Society for Reproductive 
Medicine, 2008). Amenorrhea is defined primary when menarche does not occur by the age 
of 16 years in a girl with complete secondary sexual development, or by the age of 14 years 
in a girl without secondary sexual development. Amenorrhea is defined secondary when 
menstrual cycles disappear for 6 consecutive months in a girl with irregular menses or for 3 
consecutive months in a girl with regular menses (Deligeoroglou et al., 2010). According to 
the American Society for Reproductive Medicine, currently in literature many causes of 
amenorrhea have been recognized (The Practice Committee of American Society for 
Reproductive Medicine, 2008), including: 
• anatomic defects of the genital tract 
• hypothalamic/pituitary causes 
• ovary insufficiency 
• endocrinopathies 
• chronic oligo- or anovulation 
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Treatment of amenorrhea depends on the aetiology and consists of specific diagnostic and 
therapeutic procedures. The aim of the present chapter is to summarize the most important 
and recent findings regarding primary and secondary amenorrhea. 
2. Epidemiology of amenorrhea 
It has been estimated that amenorrhea not due to physiological conditions has a prevalence 
ranging from 3% to 4% (Bachmann & Kemmann, 1982; Pettersson et al., 1973). The most 
frequent causes of amenorrhea are four: hypothalamic amenorrhea, hyperprolactinemia, 
ovarian failure, and polycystic ovary syndrome (The Practice Committee of American 
Society for Reproductive Medicine, 2008).  
3. Causes of primary and secondary amenorrhea 
The main causes of primary and secondary amenorrhea include anatomic defects of the 
genital tract, hypothalamic/pituitary causes, ovary insufficiency, endocrinopathies and 
chronic oligo- or anovulation (Table 1). 
 
Anatomic genital 
defects
Hypothalamic causes Pituitary causes Ovary insufficiency Endocrine diseases Chronic oligo- or 
anovulation
Vaginal agenesis
Transverse vaginal
septum
Imperforate hymen
Cervical agenesis or
dysgenesis
Endometrial hypoplasia 
or aplasia
Intrauterine synechiae
Mayer-Rokitansky-
Küster-Hauser
syndrome
Androgen insensitivity
syndrome
Functional hypothalamic
amenorrhea
 Psychogenic stress
 Intensive physical activity
 Nutritional disorders
Isolated gonadotropin deficit
 Kallman syndrome
 Idiopathic
hypogonadotropic
hypogonadism
Chronic diseases
Infections
Tumours
Prolactinomas
Tumours secreting
 FSH 
 LH 
 GH
 TSH 
 ACTH
Inflammatory and 
infiltrative disorders
Empty sella
Panhypopituitarism
Sheehan syndrome
Gonadal agenesis
Gonadal dysgenesis 
Premature
ovarian failure
Enzymatic deficits
Adrenal diseases 
17aHydroxylase deficiency
17,20Lyase deficiency
Aromatase deficiency
Thyropathies
Poorly controlled diabetes
Ovarian tumours
Polycystic ovary 
syndrome
 
Table 1. Etiopathology of primary and secondary amenorrhea 
3.1 Anatomic defects of the genital tract  
Anatomic genital defects include vaginal agenesis, transverse vaginal septum, imperforate 
hymen, cervical agenesis or dysgenesis, endometrial hypoplasia or aplasia, Mayer-
Rokitansky-Küster-Hauser syndrome, and androgen insensitivity syndrome.  
Vaginal agenesis should be suspected in all girls with primary amenorrhea suffering frequent 
abdominal and pelvic pain due to the anatomic barrier which obstacles blood flow. 
Furthermore, the amassing of blood in the uterus (hematometra) can provoke retrograde 
menstruation leading to the development of adherences and endometriosis (The Practice 
Committee of American Society for Reproductive Medicine, 2008). 
Transverse vaginal septum represents a congenital vaginal obstruction. There are two variety 
of transverse septum: partial and total; only the total variety is responsible for amenorrhea 
(Deligeoroglou et al., 2010). The obstruction can be located in the inferior (16%), central 
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(40%) or superior (46%) vaginal portion (Rock et al., 1982). Similarly to vaginal agenesis, also 
this defect is responsible for recurring abdominal and pelvic pain coming from blood 
accumulation in the uterus and vagina (hematocolpos) (Deligeoroglou et al., 2010). 
Imperforate hymen has been estimated having an incidence of 1/1000 (Deligeoroglou et al., 
2010). The diagnosis is uncommon during infancy because this condition is usually 
asymptomatic, although in rare cases neonates can suffer marked abdominal enlargement. 
More commonly, girls with amenorrhea will receive diagnosis of imperforate hymen after 
having abdominal pain, hematometra or hematocolpos during the pubertal period (Ameh et 
al., 2011). 
Cervical anatomic defects represent another important cause of primary amenorrhea. There 
are two types of cervical abnormality: agenesis and dysgenesis. Both these defects can be 
associated with a normal development of the vagina. In details, while in the dysgenesis a 
partial cervical development is observed, in the agenesis patients are likely to present earlier 
with a history of primary amenorrhea and severe lower abdominal pain occurring at 
irregular intervals (Deligeoroglou et al., 2010).  
Endometrial hypoplasia or aplasia represent the partial development or the congenital absence 
of endometrium.  
Intrauterine synechiae, also named Ashermann syndrome, is a condition very unusual among 
adolescents, while represents the most frequent cause of secondary amenorrhea in women 
of reproductive age. In fact, abortion, postpartum curettage for haemorrhage, or postpartum 
endometritis can provoke the development of intrauterine synechiae leading to cessation of 
menses (Deligeoroglou et al., 2010). 
Mayer-Rokitansky-Küster-Hauser syndrome is a congenital defect of the genital tract recognized 
as the more common cause of amenorrhea after gonadal dysgenesis, having an incidence of 
1/5.000 (Fedele et al., 1996). This syndrome is also called “Müllerian agenesis” because is 
characterized by absence or hypoplasia of the Müllerian ducts derivatives. In fact, the main 
features of Mayer-Rokitansky-Küster-Hauser syndrome are the following: normal ovaries, 
anomalies of the uterine development ranging from absence to rudimentary residues of 
uterus and aplasia of the upper two thirds of the vagina. Furthermore, affected women 
show the development of secondary sexual characteristics with a female 46, XX karyotype 
(Bean et al., 2009; Morcel et al., 2007). There are two types of Mayer-Rokitansky-Küster-
Hauser syndrome (Morcel et al., 2007): type 1 represents the isolated variety, while type 2 is 
associated with several organic abnormalities involving upper urinary tract (40% of cases), 
skeleton (10-12% of cases) (American College of Obstetricians and Gynecologist Committee 
on Adolescent Health Care, 2006), auditory system (10-25% of cases) (Cremers et al., 1995; 
Strübbe et al., 1994), and more rarely heart. The aetiology of Mayer-Rokitansky-Küster-
Hauser syndrome is still uncertain: although at the beginning it was supposed that this 
syndrome was the result of sporadic abnormality, it has been recently assumed a genetic 
background on the basis of a growing amount of familial cases (Morcel et al., 2007). 
Clinically, the most common presentation is characterized by primary amenorrhea in 
adolescents with normal secondary female characteristics. Just in few cases, where patients 
have rudimentary residues of uterus with a normal endometrial function, there is a history 
of recurring severe lower abdominal pain; furthermore, some adolescents can suffer 
psychological distress from unsuccessful sexual life (Deligeoroglou et al., 2010). Endocrine 
evaluation shows normal levels of basal plasma gonadotropin and sex steroid (estradiol), 
without biochemical signs of androgen excess (Carranza-Lira et al., 1999). 
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Androgen insensitivity syndrome is a rare X-linked recessive androgen receptor defect having 
an incidence of 1/20.000-99.000 (Boehmer et al., 2001; Grumbach et al., 2003). The gene 
responsible for this condition has been mapped to chromosome Xq11-12 (Brinkmann et al., 
1989), and about 30% of mutations are the result of sporadic anomalies (Hughes & Deeb, 
2006). Nowadays, three variants of androgen insensitivity syndrome have been recognized 
based on the inactivity of androgen receptor: complete androgen insensitivity syndrome, 
with a phenotype characterized by normal female external genitalia; mild androgen 
insensitivity syndrome, with a phenotype characterized by normal male external genitalia; 
partial androgen insensitivity syndrome, with a phenotype characterized by partial 
masculinization of external genitalia (Hughes & Deeb, 2006). In details, complete androgen 
insensitivity syndrome has an incidence of 1/60.000 (Jorgensen et al., 2010) and is 
characterized by congenital agenesis of the uterus and absent or rudimentary vagina in 
women showing normal development of secondary sexual characteristics in presence of a 
46,XY karyotype (Oakes et al., 2008). In addition, these patients present cryptorchidism, 
with gonads situated in the inguinal canal or abdominal cavity; testicles are functional and 
produce normal testosterone and dihydrotestosterone levels. Although usually patients 
affected by complete androgen insensitivity syndrome present primary amenorrhea 
together with scarce or absent pubic and axillary hair, girls can also present an inguinal 
hernia during infancy or childhood. In addition, since the incidence rate of complete 
androgen insensitivity syndrome has been reported to be 1%-2% in subjects with inguinal 
hernia, some authors have suggested to consider a karyotype in every girl with inguinal 
masses (Hughes & Deeb, 2006; Sarpel, 2005). The incidence of testes malignancy has been 
estimated to be 22%, although it is infrequent in subjects younger than 20 years of age 
(Manuel et al., 1976). Usually, endocrine evaluation shows high levels of basal plasma 
testosterone and luteinizing hormone, frequently in association to high levels of estradiol 
(Hughes & Deeb, 2006).  
3.2 Hypothalamic causes 
Hypothalamic diseases represent the most frequent cause of amenorrhea in adolescents 
(Deligeoroglou et al., 2010). In fact, girls with disorders of the hypothalamus are susceptible 
to the development of chronic anovulation, due to an insufficient secretion of gonadotropin-
releasing hormone leading to low levels of basal plasma gonadotropins and estradiol. 
However, after stimulation with exogenous gonadotropin-releasing hormone, the secretion 
of gonadotropins is in the physiological range. Hypothalamic amenorrhea has frequently a 
dysfunctional origin, although in rare cases it can be due to other conditions including the 
isolated deficit of gonadotropins, chronic diseases, infections, and tumours (Deligeoroglou 
et al., 2010). 
Dysfunctional causes of hypothalamic amenorrhea include psychogenic stress, excessive physical 
activity and nutritional disorders. Actually the precise mechanisms through which excessive 
stress and weight loss influence negatively gonadotropin-releasing hormone secretion are 
still uncertain (Golden & Carlson, 2008). However, in these girls the impaired production of 
gonadotropin-releasing hormone may have several implications on luteinizing hormone  
secretion, coming from absent or reduced pulses to normal or elevated pulses 
(Deligeoroglou et al., 2010). 
Psychogenic stress seems to induce the secretion of high levels of corticotrophin-releasing 
hormone, which inhibits gonadotropin-releasing hormone pulses (Deligeoroglou et al., 
2010).  
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Also girls performing excessive physical activity are prone to present hypothalamic 
amenorrhea and short luteine phases. These abnormalities are induced by the strenuous 
physical activity and the restricted caloric intake requested to maintain leanness. In fact, 
athletes show frequently a strong disproportion among nutritional intake and real energy 
expenditure, especially in disciplines where low body weight for performance and 
aesthetics is needed (Golden & Carlson, 2008). In particular, in athletes there is a risk of 
amenorrhea three times higher than in general population, with predominance between 
long-distance runners (Warren & Goodman, 2003). Interestingly, a peculiar condition called 
the “female athlete triad” has been recognized as the result of an inadequate caloric intake. 
This condition includes amenorrhea, eating disorders, and osteoporosis, and athletes can 
present one or more components of the triad. Therefore, all these alterations should be 
screened in order to perform an early diagnosis and to improve quality life of women 
involved in competitive sports (Mendelsohn & Warren, 2010). 
Eating disorders represent another common cause of functional hypothalamic amenorrhea. 
Unfortunately, these disorders are increasing worldwide and the effects on reproduction are 
more than negative. In particular, in females the reproductive axis is strongly related to the 
nutritional status and is highly responsive to external stimuli due to the high energy 
expenditure during pregnancy and lactation. Therefore, in condition of undernutrition, the 
female reproduction can be interrupted and continued in better periods to preserve vital 
functions. In fact, a decrease of 10%-15% in normal body weight seems to be able to cause 
amenorrhea (European Society of Human Reproduction and Embryology Capri Workshop 
Group, 2006). Up to now, it has been estimated that about 1%-5% of women are affected by 
the “weight related amenorrhea” (Laughlin et al., 1998). Although the responsible 
mechanisms are not entirely clear, it has been proposed a minimal body weight of 47 kg for 
the onset or maintenance of menstrual cycles (Frisch & McArthur, 1974; Frisch, 1987). 
Among the most important eating disorders, anorexia nervosa and bulimia nervosa affect 
up to 5% of women of reproductive age causing amenorrhea and infertility (European 
Society of Human Reproduction and Embryology Capri Workshop Group, 2006). In details, 
anorexia nervosa has been defined as body weight less than 85% of expected weight or body 
mass index less than 17.5 kg/m2, caloric restriction, fear of weight gain and an impaired 
perception of body image. Bulimia nervosa has been defined as binge eating followed by 
vomiting, intense physical activity and other compensatory actions (Becker et al., 1999). 
Approximately 15%-30% of girls affected by anorexia nervosa present amenorrhea (Miller et 
al., 2005; Watson & Andersen, 2003), while girls with bulimia may present oligoamenorrhea 
also in presence of a normal body mass index (European Society of Human Reproduction 
and Embryology Capri Workshop Group, 2006). The mechanisms underlying preservation 
or discontinuation of the physiological neuroendocrine regulation of ovarian function in 
girls with anorexia or bulimia are still unknown. However, it has been supposed the 
occurrence of impaired gonadotropin-releasing hormone secretion with alterations in 
dopaminergic and opioid systems. Recently, low levels of luteinizing hormone and estradiol 
have been demonstrated in women with hypothalamic amenorrhea, togheter with 
gonadotropins pulses insufficient to protract the development of follicles until ovulation 
(Welt et al., 2004). Furthermore, the lately discovered leptin, one of the most important 
adipose derived hormones which plays a key role in regulating energy intake and 
expenditure, seems to be strictly involved into the mediation of reproductive axis (Brennan 
& Mantzoros, 2006). In fact, low levels of leptin have been reported in women with 
hypothalamic amenorrhea (Welt et al., 2004). Although it is still unclear if leptin has direct 
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hypothalamic effects or augments the metabolic substrates availability, it is probable that 
this hormone mediates both these effects.  
Isolated deficit of gonadotropins represents a rare cause of hypothalamic amenorrhea, including 
the Kallman syndrome and the idiopathic hypogonadotropic hypogonadism.  
The Kallman syndrome represents a genetic heterogeneous developmental disease 
characterized by gonadotropin-releasing hormone deficiency and defective development of 
olfactory nerves, bulbs and sulci, with an incidence of 1/40000 girls and 1:8000 boys (Dodé 
& Hardelin, 2009). This disorder can be autosomal-dominant with incomplete penetrance, 
autosomal-recessive, X-linked recessive, or can have an oligogenic/digenic inheritance 
pattern (Dodé & Hardelin, 2009; Jana & Kumar, 2010). Up to now, five genes have been 
implicated into the pathogenesis of the disease: KAL1 (Franco et al., 1991; Hardelin et al., 
1992), FGFR1 (Dodé et al., 2003), FGF8 (Falardeau et al., 2008), PROKR2 and PROK2 (Dodé 
et al., 2006). However, a smaller amount (around 30%) of affected subjects present mutations 
in any of these genes. Affected women present hypogonadotropic hypogonadism, 
amenorrhea and absence of secondary sexual characteristics together with hyposmia or 
anosmia (Seminara et al., 1998). Generally, the diagnosis is performed during adolescence 
on the basis of reproductive and olfactory disorders. However, patients with Kallman 
syndrome can present further characteristics as well as mental retardation, cerebellar ataxia, 
cardiovascular anomalies, cranio-facial alterations, renal agenesis, hearing impairment, and 
abnormal visual spatial alterations (Quinton et al., 2001).  
The Idiopathic Hypogonadotropic Hypogonadism is a rare genetic disease caused by a deficiency 
of hypothalamic gonadotropin-releasing hormone release; however, this disorder can be 
also caused by an impaired action of gonadotropin-releasing hormone on gonadotropes 
cells in the pituitary (Bianco & Kaiser, 2009). Idiopathic hypogonadotropic hypogonadism 
has been suggested to be the result of isolated functional anomalies of the neuroendocrine 
signals for release of gonadotropin-releasing hormone or gonadotropins. In fact, in these 
subjects no developmental or anatomical alterations of the hypothalamus-pituitary-
gonadotropin axis have been described; the affected patients present a normal olfaction in 
presence of a phenotype deriving from pre- and postnatal gonadotropins and sex steroid 
deficiency (Brioude et al., 2010). Hypogonadotropic hypogonadism may be also due to 
mutations in gonadotropin-releasing hormone receptor genes (Layman et al., 2001).  
Active, uncontrolled or untreated chronic diseases responsible for hypothalamic amenorrhea 
include malabsorption, acquired immune deficiency syndrome, diabetes, and kidney 
disorders (The Practice Committee of American Society for Reproductive Medicine, 2008).  
Infections include meningitis, encephalitis, syphilis, and tuberculosis (The Practice 
Committee of American Society for Reproductive Medicine, 2008).  
Possible tumours causing hypothalamic amenorrhea include craniopharyngioma, Langerhans 
cell histiocytosis, hamartoma, germinoma, endodermal sinus tumor, teratoma, metastatic 
carcinoma (The Practice Committee of American Society for Reproductive Medicine, 2008).  
3.3 Pituitary causes 
The main pituitary disorders responsible for amenorrhea include tumours, 
inflammatory/infiltrative disorders, panhypopituitarism and empty sella syndrome 
(Deligeoroglou et al., 2010).  
Possible pituitary tumours causing amenorrhea include prolactinomas, and other tumours 
secreting hormones such as adrenocorticotropic hormone, thyrotropin-stimulating hormone, 
growth hormone, gonadotropins (luteinizing hormone, follicle-stimulating hormone). 
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Hyperprolactinemia represents the most frequent cause of amenorrhea of pituitary origin, 
being responsible for 1% of cases of primary amenorrhea (Patel & Bamigboye, 2007). In fact, 
high levels of prolactin suppress hypothalamic gonadotropin-releasing hormone release 
determining a reduction of estradiol levels. It is fundamental to recognize the origin of 
prolactin hypersecretion. In fact, in women with hyperprolactinemia it has been estimated a 
prevalence of pituitary tumours of approximately 50-60% (Brenner et al., 1985). However, it 
is important to rule out also any other cause responsible for rise in prolactin levels, 
including macroprolactinemia, hypothyroidism, stress, antipsychotics and masses reducing 
dopamine release; in fact, prolactin pituitary release is principally inhibited by dopamine 
(Asa & Ezzat, 2009). Furthermore, in women with mild prolactin increase it is common to 
find altered inhibiting systems (Deligeoroglou et al., 2010). 
Among the pituitary disorders responsible for amenorrhea, Sheehan’s syndrome represents 
a form of hypopituitarism resulting from ischemic pituitary necrosis caused by severe 
postpartum haemorrhage, especially in developing countries (Kelestimur, 2003). Up to now 
the pathogenesis of this syndrome is still unknown although it has been proposed that 
during pregnancy the enlarged pituitary gland, small sella dimension, autoimmunity and 
disseminated intravascular coagulopathy could play a pivotal role. A variety of signs and 
symptoms have been described in women affected by Sheehan’s syndrome, including 
tiredness, weakness, agalactia, amenorrhea and partial to total hypopituitarism. The 
majority of affected women show empty sella on computer assisted tomography or 
magnetic resonance imaging. It has been recommended to consider primary empty sella 
syndrome and lymphocytic hypophysitis among differential diagnosis.  
Systemic inflammatory/infiltrative diseases, like hemocromatosis and sarcoidosis, represent less 
frequent pituitary causes of amenorrhea (Deligeoroglou et al., 2010). 
3.4 Ovary insufficiency 
Ovary insufficiency includes a wide spectrum of diseases characterized by 
hypergonadotropic hypogonadism due to an insufficient production of sex steroids in 
presence of high follicle-stimulating hormone and luteinizing hormone levels. 
Hypergonadotropic hypogonadism can be due to several conditions including gonadal 
agenesis or dysgenesis, premature ovarian failure and enzymatic deficits; each of these 
conditions includes many other disorders (Deligeoroglou et al., 2010).  
Gonadal dysgenesis includes those situations characterized by anomalous development 
causing streak gonads. These conditions can take place in patients with abnormal as well as 
normal karyotype. 
Turner Syndrome represents the most frequent chromosomal abnormality responsible for 
gonadal dysgenesis, having an incidence of approximately 1/2500 live female births 
(Nielsen & Wohlert, 1991). The diagnosis of Turner syndrome is performed on the basis of 
typical phenotypic characteristics in phenotypic girls females (Turner, 1938; Ullrich, 1930) 
having partial or total absence of one X chromosome, with or without mosaicisms 
(Ferguson-Smith, 1965). The key features of Turner syndrome are webbing of the neck, 
misshapen ears, broad chest, widely spaced nipples, cubitus valgus, cardiac malformations, 
renal diseases and short stature (Morgan, 2007). Furthermore, one of the most frequent 
characteristics of Turner syndrome is the lack of pubertal development. In fact, although the 
ovaries develop normally, they degenerate during intrauterine life and infancy, and more 
than 90% of females will present gonadal failure (Bondy et al., 2007). However, 
approximately 30% of these patients will present natural pubertal development (Boechat et 
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al., 1996; Pasquino et al., 1997), and menses will occur in 2-5% of girls having 46,XX/45,X 
mosaicism due to a normal oocytes amount; furthermore, about 5% of girls with Turner 
syndrome will present spontaneous pregnancy (Hovatta, 1999). 
Gonadal dysgenesis can happen also in subjects with 46,XY or 46,XX karyotype. In 
particular, subjects with 46,XY karyotype are known to be affected by Swyer syndrome. 
These subjects present female external or ambiguous genitalia with normal development of 
vagina and uterus due to the absent or inadequate production of anti-Mullerian hormone 
and testosterone (Barbaro et al., 2007). It has been estimated that approximately 25% of 
subjects with diagnosis of Swyer syndrome develop gonadal tumours; for this reason, it is 
necessary to remove gonads at the diagnosis (Manuel et al., 1976). 
Premature ovarian failure refers to primary ovarian defect occurring in women younger than 
40 years of age. This condition can be responsible for primary amenorrhea, or secondary 
amenorrhea when there is premature oocytes depletion and/or reduced folliculogenesis 
(Santoro, 2003; Timmreck & Reindollar, 2003). It has been estimated a premature ovarian 
failure incidence of approximately 1/1000 women under the age of 30 years, 1/250 around 
the age of 35 years and 1/100 at the age of 40 years (Timmreck & Reindollar, 2003). 
Furthermore, it has been described a familial form of premature ovarian failure which 
accounts for 4-31% of cases (Conway et al., 1996; Cramer et al., 1995; Torgerson et al., 1997). 
Premature ovarian failure can have different causes: iatrogenic after surgery or treatment of 
cancer (Santoro, 2003), autoimmune, infective (mumps oophoritis, cytomegalovirus, herpes 
zoster) and metabolic (galactosemia) (Beck-Peccoz & Persani, 2006). However, the major 
part of all cases of premature ovarian failure is idiopathic, and a genetic aetiology has been 
suggested on the basis of candidate genes found in some families (Van Kasteren & 
Schoemaker, 1999). In fact, disorders of the X chromosome have been found to be related 
with premature ovarian failure in women with Turner syndrome, partial X deletions or 
translocation, or presence of an extra X chromosome (Goswami & Conway, 2007). In 
particular two genes, respectively POF1, localised on Xq21.3–Xq27, and POF2, localised on 
Xq13.3–q21.1, have been found to be associated with chromosomal anomalies responsible 
for POF development (Beck-Peccoz & Persani, 2006). However, numerous other genes have 
been implicated in females with premature ovarian failure, including BMP15, FMR1, FMR2, 
LHR, FSHR, INHA, FOXL2, FOXO3, ERa, SF1, ERb and CYP19A1 genes (Cordts et al., 2011). 
Clinically, the presentation is characterized by primary amenorrhea in adolescents without 
secondary female characteristics, or disappearance of menses in women with normal 
pubertal development, palpitations, flushes, tiredness and depression. Endocrine evaluation 
shows high basal gonadotropins levels and low estradiol and inhibin values (Beck-Peccoz & 
Persani, 2006).  
3.5 Endocrinopathies 
The spectrum of endocrinopathies is broad and includes adrenal diseases (including 17-a-
Hydroxylase deficiency, 17,20-Lyase deficiency, aromatase deficiency), thyropathies, poorly 
controlled diabetes and ovarian disorders (Deligeoroglou et al., 2010). 
3.6 Chronic oligo- or anovulation  
Chronic oligo- or anovulation refers to polycystic ovary syndrome, an eterogeneous 
endocrinopathy characterized by a broad spectrum of clinical and biochemical features. In 
fact, this complex disorder requires the presence of several phenotypes, including 
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hyperandrogenism and/or hyperandrogenemia, and normoovulation or oligoovulation 
with or without polycystic ovaries (Azziz et al., 2006). This phenomenon has been described 
in at least 6% of women during the reproductive years (Rosenfield, 2007). However, it has 
been recently reported that using different diagnostic criteria the prevalence of polycystic 
ovary syndrome was approximately 18% (March et al., 2010). The etiopathogenesis of 
polycystic ovary syndrome is still unclear although it seems a combination of genetic and 
environmental factors. In particular, two conditions have been recognized as playing a 
major role: insulin resistance with hyperinsulinemia and hyperandrogenism (Teede et al., 
2010). In addition, hypothalamic/pituitary disorders, ovarian disorders failure and obesity 
are implicated in the pathogenesis of polycystic ovary syndrome (Doi et al., 2005; Legro & 
Strauss, 2002). This syndrome becomes symptomatic already during adolescence (Azziz et 
al., 2004; Franks et al., 2006) with psychological, metabolic and reproductive symptoms, 
including depression, anxiety (Deeks et al., 2010), hirsutism, oligoamenorrhea or 
amenorrhoea, infertility (Boomsma et al., 2006), metabolic syndrome, type 2 diabetes and 
cardiovascular diseases (Apridonidze et al., 2005; Legro et al., 1999). In particular, 70% to 
80% of women with polycystic ovary syndrome show oligoamenorrhea or amenorrhoea 
caused by chronic oligo-ovulation/anovulation (Brassard et al., 2008; Teede et al., 2010). 
4. The assessment and investigation of amenorrhea 
According to the American Society for Reproductive Medicine, the investigation of 
amenorrheic girls should be started by 15 years of age in girls with normal secondary sexual 
development as well as in girls presenting thelarche before 10 years of age but without 
menses within 5 years, and in girls without secondary sexual development until 13 years of 
age (The Practice Committee of American Society for Reproductive Medicine, 2008). 
Diagnostic features of primary and secondary amenorrhea are reported in Table 2. 
4.1 Medical history 
The first step in the evaluation of amenorrheic girl should be based on the patient and family 
history (Master-Hunter & Heiman, 2006). The physician should conduct a complete patient 
history including growth and pubertal pattern, congenital anomalies, preceding or existing 
chronic or autoimmune diseases, anosmia, galactorrhea, recurring abdominal and/or pelvic 
pain, headache, vomiting, nausea, visual changes or double vision, preceding central 
nervous system radiation or chemotherapy and/or pelvic radiation, legal or illegal drug 
utilize, psychological distress, nutritional and exercise pattern, menarche, menstrual history, 
sexual life. In particular, date of menarche and records of menses should be extremely 
accurate. The family history should include growth and pubertal pattern, menarche and 
menstrual history of mothers and sisters, infertility, genetic disorders, chronic or 
autoimmune diseases, disorders or signs of androgen excess, hypo/hypertrichosis of pubis. 
4.2 Physical examination 
A complete physical evaluation should be carefully performed (Master-Hunter & Heiman, 
2006), including anthropometric measurements [height, height standard deviation score, 
weight, body mass index, body mass index standard deviation score, growth velocity], 
staging of pubertal development according to the criteria of Marshall and Tanner (Marshall 
& Tanner, 1969), signs of androgen excess (acne, hirsutism, deepening of the voice), signs or 
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Clinical aspects Laboratoristic features Instrumental procedures
Anatomic genital defects -Frequent abdominal and pelvic pain
-Hematometra/hematocolpos
-Normal secondary female characteristics, 
except in:
 mild androgen insensitivity syndrome 
(male external genitalia)
 partial androgen insensitivity syndrome 
(partial masculinization of external
genitalia)
-Scarce or absent pubic/axillary hair, 
inguinal masses (complete androgen 
insensitivity syndrome)
-In Mayer-Rokitansky- Küster-
Hauser syndrome:
 normal levels of basal 
gonadotropins and sex steroids
 no hyperandrogenism
 46,XX karyotype
-In complete androgen insensitivity
syndrome:
 high levels of basal LH and 
testosterone, frequently with high 
levels of estradiol
 46,XY karyotype
-Pelvic ultrasonography and 
magnetic resonance imaging: 
 anatomic defects
-Hysteroscopy or salpingogram:
 intrauterine synechiae
Hypothalamic causes -Low body weight (functional hypothalamic 
amenorrhea)
-Absence of secondary sexual characteristics, 
hyposmia/anosmia
(Kallman syndrome)
-Normal olfaction with a phenotype deriving 
from pre- and postnatal gonadotropins and 
sex steroid deficiency (idiopathic 
hypogonadotropic hypogonadism)
-Insufficient secretion of GnRH
leading to low levels of basal 
gonadotropins and estradiol
-After stimulation with exogenous 
GnRH, gonadotropins secretion is in 
the physiological range
-Low levels of leptin
Magnetic resonance imaging:
 normal or altered anatomy/ 
development of the hypothalamus
Pituitary causes -Galactorrhea (prolactinomas) -High levels of prolactin
-Suppression of GnRH release
-Reduction of estradiol levels
Magnetic resonance imaging:
 empty sella
 normal or altered anatomy/ 
development of the pituitary gland
Ovary insufficiency -Lack of pubertal development, webbing of 
the neck, misshapen ears, widely spaced 
nipples, cardiac malformations, renal 
diseases, short stature (Turner syndrome)
-Female external or ambiguous genitalia with 
normal vagina and uterus (Swyer syndrome)
-Primary amenorrhea without secondary 
characteristics, or secondary amenorrhea in 
girls with normal puberty (ovarian failure)
-High FSH and LH levels
-Estrogen deficiency 
-Low inhibin levels
-Karyotype :
 46,XX
 45,X
 46,XX/45,X mosaicism
 46,XY
Pelvic ultrasonography:
 streak gonads
 absent or reduced follicular 
activity  
Chronic oligo- or anovulation -Signs of androgen excess: acne, hirsutism, 
deepening of the voice
-Obesity, metabolic syndrome, type 2 
diabetes, cardiovascular diseases
-Oligoamenorrhea or amenorrhoea
-Hyperandrogenemia
-Insulin resistance
-Hyperinsulinemia
Pelvic ultrasonography:
 polycystic ovaries
 
Table 2. Diagnostic features of primary and secondary amenorrhea 
symptoms of systemic diseases or endocrine disorders (goiter, central obesity, purplish skin 
striae, muscle weakness), and stigmata of genetic anomalies (short stature, misshapen ears, 
broad chest, widely spaced nipples, cubitus valgus). Systolic blood pressure and diastolic 
blood pressure should be measured to exclude hypertension. Therefore, the physician 
should perform a careful examination of the external genitalia to assess clitoris, hymen 
permeability and vaginal and uterine development (Adams Hillard, 2008).  
4.3 Laboratory evaluation 
Laboratory evaluation of amenorrheic adolescents should include the measurements of basal 
plasma gonadotropins, estradiol, progesterone, free and total testosterone, 
dehydroepiandrosterone sulphate, delta4-androstenedione, 17-OHprogesterone, thyroid 
function tests (free triiodothyronine, free thyroxine, thyrotropin, anti-thyroglobulin 
antibodies, anti-thyroid peroxidase antibodies, anti-thyrotropin receptor antibodies), 
prolactin, fasting insulin and glucose, insulin resistance indexes, adrenocorticotropic 
hormone, cortisol, markers of ovarian tumours. Because pregnancy represents the most 
frequent cause of secondary amenorrhea, urine or serum pregnancy test is obligatory in 
adolescents with irregular menses (Master-Hunter & Heiman,2006). It has been suggested to 
perform the “progesterone challenge test” in those females with secondary amenorrhea and 
androgen in the normal range in order to measure circulating estrogens values and identify 
an insufficient endometrial estrogenization (Deligeoroglou et al., 2010). 
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It can be also very important to detect peak plasma gonadotropins response to exogenous 
gonadotropin-releasing hormone to detect a defect of hypothalamic-pituitary axis. 
Karyotype should be requested in case of suspected genetic anomalies.  
4.4 Instrumental evaluation 
The instrumental procedures are crucial in the evaluation of primary and secondary 
amenorrhea. Pelvic transabdominal ultrasonography scanning should be performed by a 
trained and experienced operator to measure length, breadth, and depth of uterus and 
ovaries, and endometrial thickness. Furthermore, magnetic resonance imaging of the 
hypothalamus and pituitary gland, and magnetic resonance imaging of the pelvis are of 
pivotal importance. In some cases, it can be necessary to perform hysteroscopy or 
hysterosalpingogram to assess the presence of intrauterine synechiae (The Practice 
Committee of American Society for Reproductive Medicine, 2008). 
5. Treatment of amenorrhea 
Amenorrhea and the related disorders require appropriate treatments (Table 3). 
 
Therapeutic approaches
Anatomic genital defects - Surgical correction
- Gonadectomy followed by exogenous estrogens (complete androgen insensitivity syndrome)
Hypothalamic causes - Estrogens and progestin replacement therapy 
- Calcium and vitamin D supplementation
- Reduced physical activity, weight gain
- Surgical removal of tumours
Pituitary causes - Dopamine agonists: cabergoline or bromocriptine (prolactinomas)
- Surgical removal (tumours)
- Estrogens and progestin replacement therapy
Ovary insufficiency - Estrogens replacement therapy at approximately 12 years of age at low-doses, followed by a gradual 
augment over 2–4 years. Progestin should be started after at least 2 years or at uterine bleeding. Calcium 
supplementation (Turner syndrome)
- Estrogens replacement therapy after gonadectomy at approximately 11 years of age (Swyer syndrome)
- Estrogens replacement therapy until the normal age of menopause; for females having a whole uterus 
combined estrogens and progestin hormone therapy; physical activity, diet rich in calcium and vitamin D 
(premature ovarian failure)
Endocrine diseases Appropriate therapy
Chronic oligo- or anovulation - Increased physical activity, reduced food intake
- Estrogen replacement therapy at low doses combined with cyclic progestin 
- Insulin-sensitising drugs (metformin)
 
Table 3. Therapeutic approaches for primary and secondary amenorrhea 
5.1 Treatment of the anatomic defects of the genital tract 
Every anatomic defect of the genital tract requires appropriate surgical procedures. In 
particular, transverse vaginal septum require the excision, imperforate hymen necessitates 
the elimination of the tissue in a triangular form and intrauterine synechiae require their 
removal. Furthermore, cervical agenesis may require hysterectomy while cervical 
dysgenesis may necessitate cervical canalization (Deligeoroglou et al., 2010). 
Regarding to Mayer-Rokitansky-Küster-Hauser syndrome, patients may benefit by surgical 
formation of a neovagina; undeveloped uterus should be removed in presence of functional 
endometrium as it can be responsible for uterus swelling and recurrent lower abdominal 
pain. Finally, in girls with diagnosis of androgen insensitivity syndrome a vaginal length 
adequate for intercourse could be reached through non surgical dilatation. However, in 
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some cases surgical correction of genital tract anomalies should be performed in order to 
create a neovagina. Both in girls affected by Mayer-Rokitansky-Küster-Hauser syndrome 
and androgen insensitivity syndrome it is imperative to guarantee a constant psychological 
support (Deligeoroglou et al., 2010). 
5.2 Treatment of hypothalamic and pituitary disorders 
Hypothalamic amenorrhea should be treated according to its aetiology. In particular, 
treatment of functional hypothalamic amenorrhea should be finalised to the appearance or 
regulation of menstrual cycles by starting estrogens and progestin therapy. Furthermore, 
this therapy should prevent the development of osteoporosis. Respect to oral estrogens, it 
has been demonstrated that transdermal hormone replacement therapy has better effects on 
bone density than oral hormone replacement therapy due to the absence of the first-pass 
hepatic metabolism (Jayasinghe et al., 2008). In addition, calcium and vitamin D 
supplementation is highly suggested (Master-Hunter & Heiman, 2006). In particular, in 
athletes with the “female athlete triad” treatment targets to restore menses through reduced 
physical activity, weight gain, calcium supplementation and estrogen  therapy (American 
Academy of Pediatrics Committee on Sports Medicine and Fitness, 2000).  
Regarding to the Kallmann syndrome, the treatment targets to promote breast development 
through estrogens and progestin replacement therapy in girls and to promote virilization 
through testosterone replacement therapy in males. Furthermore, hormonal treatments can 
be offered as a valid method for restoring fertility in these patients. Both pulsatile 
gonadotropin-releasing hormone or gonadotropins administration have been utilized to 
stimulate ovulation in females and spermatogenic activity in males (Buchter et al., 1998). 
Also in the majority of subjects affected by idiopathic hypogonadotropic hypogonadism, 
long-term exogenous pulsatile gonadotropin-releasing hormone therapy has been proven to 
be efficient because it induces testicular growth and development of sperm in the ejaculate, 
favours sexual life and improves reproductive prognosis. However, a minor part of this 
population did not respond to gonadotropin-releasing hormone replacement, suggesting 
that pituitary and testicular defects in these subjects are improbable to be totally 
consequences of gonadotropin-releasing hormone deficiency (Sykiotis et al., 2010).  
Regarding to prolactinomas, therapy should target to restore menses and guarantee fertility. 
Dopamine agonists are the favourite treatment of hyperprolactinemia because they are able 
to reduce prolactin levels, to decrease the tumor size and to restore gonadal function (Iyer & 
Molitch, 2011). Actually, two dopamine agonists are used to treat prolactinomas: 
bromocriptine and cabergoline. In particular, cabergoline has been shown to be more 
efficacious with less adverse effects than bromocriptine in females with microadenomas 
(Webster et al., 1994). Therefore, cabergoline represents the principal therapeutic approach. 
Also females with macroadenoma can benefit by dopamine agonists or, in some cases, they 
must underwent surgical removal of tumours (Master-Hunter & Heiman, 2006).  
Sheehan’s syndrome requires the general standard of treatment of patients presenting with 
hypopituitarism, aiming to replace the endocrine deficits. In particular, because these 
patients are at increased risk of developing partial loss of feminization, amenorrhea and 
osteoporosis, they should start hormone replacement therapy (Kelestimur, 2003).  
5.3 Treatment of ovary insufficiency-related diseases 
Turner syndrome requires growth-promoting treatments aimed to obtain a normal 
progression of puberty and the achievement of a normal adult height. Growth hormone 
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represents the focus of growth-promoting therapy as this therapy is able to improve growth 
velocity and final height (Bondy et al., 2007). Regarding to the induction of puberty, it is 
opportune to dose gonadotropins levels before starting hormone replacement therapy to 
rule out a delayed puberty. Recent data have demonstrated that treatment with estrogens 
should begin at approximately 12 years of age to promote a normal pubertal development 
without interfering with growth hormone therapy on final height. Actually, oral estrogens 
as well as transdermal and injectable depot forms of estradiol are available (Ankarberg-
Lindgren et al., 2001; Rosenfield et al., 2005). Estradiol therapy is generally initiated at low-
doses (from 1/10 to 1/8 of the adult dose) followed by a gradual augment over 2–4 years, 
while progestin should be started after at least 2 years or when uterine bleeding happens to 
permit a regular uterine and breast development (Bondy et al., 2007). In addition, calcium 
supplementation has been highly suggested in Turner syndrome. 
In Swyer syndrome, estrogens replacement therapy should be started after gonadectomy at 
approximately 11 years of age in order to allow a normal pace of puberty (Han et al., 2008).  
Women with diagnosis of premature ovarian failure should undergo estrogens replacement 
therapy until the normal age of menopause to replace deficit of ovarian estrogens and to 
counter menopausal symptoms. In particular, for those females having a whole uterus it is 
preferable to start combined estrogens and progestin hormone therapy to avoid hyperplasia 
of the endometrium (Shelling, 2010). Due to estrogen deficiency, women with premature 
ovarian failure are also at risk of osteoporosis (Rebar, 2009); for this reason, physical activity, 
diet rich in calcium and vitamin D without smoking or alcohol consumption are mandatory. 
5.4 Treatment of chronic oligo- or anovulation 
Overweight or obese women with polycystic ovary syndrome presenting oligomenorrhoea 
or amenorrhoea should underwent structured lifestyle interventions, including increased 
physical activity and reduced food intake (Moran et al., 2009). In fact, it has been 
demonstrated that a weight loss of 5-10% is associated with beneficial effects on 
reproductive system (Huber-Buchholz et al., 1999). Regarding to pharmacological treatment, 
actually there is no therapy able to completely resolve hormonal disturbances in polycystic 
ovary syndrome. Furthermore, pharmacological treatments should not substitute the 
lifestyle interventions (Teede et al., 2010). Estrogen replacement therapy at low doses 
combined with cyclic progestin  can be started leading to a reduction of hyperandrogenism. 
Furthermore, insulin-sensitising drugs represent a valid approach to reduce insulin 
resistance in polycystic ovary syndrome (Meyer et al., 2007). In particular, metformin has 
been proven to improve ovulation and regulate menstrual periods (Tang et al., 2009).  
6. Conclusion 
Future research is needed to clarify amenorrhea and the related endocrine disorders in order 
to make an early diagnosis and to identify the more appropriate strategies during 
reproductive years of life. 
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